MKI67 and neoplasm: When used in patients with good performance status, with low-tumor burden and low-grade NETs, even better if with Ki-67 index ≤5%, and as first-line therapy, SSAs ensure prolonged progression free survival and a low but not negligible objective response rate, together with good control of endocrine symptoms and life quality, while severe adverse events and treatment discontinuation are rarely reported.